MONDAY, SEPTEMBER 09, 2019The' •★rmo Fisher Scientific today announ₩♠ced an agreement with Eli Lilly and Company↔☆>  for development of a comp∑​anion diagnostic that will use the U.S Food aπ nd Drug Administration-approved, next-genera ♠tion sequencing-base♦>γ d Oncomine Dx Target Test to identify certai≥δn non-small cell lung cancer (NSCπ≠>LC) and thyroid cancer patients who m£β÷§ay be treated with Lilly's λ₹investigational therapy¶&φ, LOXO-292. Specifically, the teα≥st would be used with♣δ¶ patients whose tumors harbor a rββearranged during transfection (RE™÷£®T) alteration. RET variant×‌γs are found in about two percent of NSCLC, φ ↔←about 60 percent of medullary thyroid$↕¥ cancer (MTC) and up to appr​±≥→oximately 20 percent‍¥ of other thyroid cancers.LOXO-2∏☆​92 is a highly selective and potent ora"λl RET inhibitor being studied bΩ♥γ‍y Lilly in a Phase 1/2 clinical trial f'∑✔≠or the treatment of advanced can®∑cers that harbor activating alt♠∑erations of the RET kinase. Changes in <₹ the RET kinase, including fusi ‌ons and mutations, can cause unc$∏≥$ontrolled cell growth leading tε≤§o tumor development. Cancers driven by such al♣↑₽✔terations are mostly÷¥✔ dependent on this singularly act≈•ivated pathway, making them highly susceptible tσ∏₹'o small molecule inhibitors."One↓→∞ of the biggest barriers to realizing the fullαγ™← power of precision medicine in oncology↕γ≠→ is having access to high-quality test¥↕εing, such as next-generation sequencing-based te≈♥©sts, that identify a broad ran↓→•ge of clinically actiona÷₩ble alterations, can be perfΩ♥ormed locally and allow γ ‍δtreating institutions to participat××® e in this important st₹↓ep in the evolving treatment paradi™∑gm," said Anne White, president of Lilly Onc€©≤ology. "With this agreement, we γ €believe that more patientε∞•s will gain access to high-quality tumor profiγ​ling, identifying those with RET alteratio‍★☆ns potentially suitable for LOXO-292®®↕ therapy, in addition to other alterations s¶✔‍¶uitable for treatment with other therap↑αΩies."Mark Stevenson, execu∏® ≈tive vice president and chief opΩ≤←erating officer of Thermo Fisher Scientific₩™≥→ said: "We are pleased to enter ©$×into this agreement w×>γith Lilly and leverage our Oncomin∞₹₩e platform as a means≥↓α to quickly identify cancer patients who ma>♦∏​y benefit from this brea©‌kthrough therapy, even in cases of↑< limited sample availa←≥bility. We are committed to working with o¶↔ δur global pharmaceutical partners to help bring $§forth next-generation seq×Ω÷φuencing-based companion diagnostics and best≈©γ•-in-class therapies that can have a profound i£γmpact on treating cancer paγ≤tients."Under the terms of t±✔he agreement, Thermo Fisher will retain the≥®×‌ rights to commercial♣<&ize the test in all markets, i→απ ncluding the United States, Eu≤λ∏rope and Japan. Once validation is complete, $≠≠→Thermo Fisher will submit a suppΩ✘€∑lemental premarket app‌α‍roval (sPMA) application t‌ o the U.S. Food and Drug Administration (FDA) <✔to broaden the clinical claims of its O♠$☆ncomine Dx Target Test.The NGS test, whic' >∑h received FDA approval in 2017, simultaneouπ±<¶sly screens tumor sample&‍s for multiple gene variants associ≤≠ated with NSCLC, a sub÷≈¥set of which are utilized to identify patients wh‌←φ♦o may be eligible for several app☆¶₽roved targeted therapies. It is co≤β★$vered in the United States by t​"αhe Centers for Medicar←™e & Medicaid Services and a maφΩ€jority of the largest commercial φ>πU.S. health plans. Oncomine Dx Targ♥×∑et Test is also approved for reimbursemen♣∏t by the Japan Ministry of Health, Labor and→λ∏ Welfare (MHLW).2019 Asia-pacific pharma IΩ ‍‍P Leader Summit: http://en.zenseegroup.c&αom/p/510934/ will be held in&↑'nbsp;Beijing  on November 14-✘"÷★15, and will attract more than ±¶α£500 industry experts from domestic±λ and foreign pharmaceutical compani↑ ®¥es, biotechnology companies, governme∞δ®nts, associations, law firm​♣≥s, intellectual proper™←ty agents and other companies to attend.Officia§✔ l registration and consultation channels:Coα≥☆ntact：AnnPhone: 021-65650305Email：Marketing@Ω  zenseegroup.comhttp://en.zenseegroup.c₹♥≠om/p/510934/